Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells

Figure 1 Treatment with Farrerol improved cardiac performance and histopathology in diabetic cardiomyopathy mice. A: Representative M-mode and pulse-wave Doppler echocardiograms of the mitral inflow (n = 8); B and C: Statistical analysis of the left ventricular ejection fraction and left ventricular fractional shortening in mice from indicated groups (n = 8); D and E: Interstitial fibrosis was detected by Masson's trichrome and Sirius red staining. Scale bars: 100 μm; F and G: Quantitative analysis of serum creatine kinase-MB and lactate dehydrogenase levels by ELISA (n = 8). ^aP < 0.05 vs NC; ^bP < 0.05 vs DCM. Eight biological replicates were included in the experiment, and the results are shown as scatter plots. FA: Farrerol; DCM: Diabetic cardiomyopathy.